Conditions: Chronic Hepatitis C Virus (HCV Infection Genotype 1)
Keywords: Treatment naive Hepatitis C Genotype 1
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
This open-label study will evaluate the safety and efficacy of co-formulated ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with or without ribavirin administered for either 4 or 6 weeks in treatment naive adults with chronic HCV-genotype 1 infection without cirrhosis

Detailed description:

Arms:
arm 1: Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.

Interventions: intervention 1: ombitasvir/paritaprevir/ritonavir, dasabuvir intervention 2: sofosbuvir (SOF) intervention 3: ribavirin (RBV)
Intervention descriptions: intervention 1: tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet intervention 2: tablet intervention 3: tablet

Protocol document: